- Global Pharma News & Resources

PerkinElmer Introduces First Ready-to-use HTRF® and AlphaLISA® Assay Kits for CHO HCP Impurities Detection and Quantification

New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics

WALTHAM, Mass. – April 4, 2022PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced two ready-to-use HTRF® and AlphaLISA® no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing. Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities to prevent immunogenicity or reduced potency, stability or overall effectiveness of a drug.

PerkinElmer's HTRF and AlphaLISA CHO HCP kits are the first on the market designed for ready-to-use homogeneous, no-wash assays for the detection and quantification of CHO HCP impurities. These off-the-shelf kits are designed to deliver a streamlined workflow,  a broader dynamic range and higher sensitivity than traditional multi-step ELISA assays. The kits are also easily automatable and can be miniaturized to a small sample volume, significantly increasing throughput to 384-well plates.

"The ability to quickly and easily detect, quantify and subsequently eliminate CHO HCP impurities during biopharmaceuticals manufacturing has continued to be a key challenge," said Alan Fletcher, senior vice president life sciences at PerkinElmer. "These innovative HTRF and AlphaLISA assay kits are designed to make this critical step more effective and efficient within existing workflows and contribute to quality control and successful biotherapeutics."

The addition of these assays further propels PerkinElmer’s ability to provide scientists with end-to-end workflow solutions spanning from early stage drug discovery and development with assays, cell lines, microplates and plate readers, into later stage research and development with high-content screening, image analysis and data management, automated liquid handling and more.

Learn more about the new AlphaLISA and HTRF assay kits here and about PerkinElmer’s drug development technologies here.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5.0 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at Follow PerkinElmer on LinkedIn, Twitter, Facebook, Instagram, and YouTube.


Last Updated: 05-Apr-2022